BioCardia's CardiAMP-HF Trial Shows Two-Year Survival, Reduced Cardiac Events

The Phase 3 CardiAMP-HF study, conducted by BioCardia, evaluated a novel cell therapy for ischemic heart failure and yielded promising results, particularly for patients with elevated NTproBNP biomarkers. Although the primary endpoint did not achieve statistical significance, subgroup analyses indicated that patients receiving CardiAMP therapy alongside standard medication experienced improved survival and reduced rates of major adverse cardiac and cerebrovascular events (MACCE). The trial involved 115 patients across 18 centers in the U.S. and Canada, revealing a 13% reduction in heart death equivalents and a notable improvement in quality of life measures. CardiAMP therapy, which utilizes a patient's own marrow cells, was presented at the American College of Cardiology's Annual Scientific Session and has received FDA Breakthrough designation. BioCardia's CEO emphasized the therapy's potential to address a significant unmet need in heart failure treatment. The positive outcomes have contributed to an uptick in BioCardia's stock performance, reflecting investor confidence in the therapy's future potential.